NKG2D stim 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NKG2D-ACE2 CAR-NK cells / Chongqing Sidemu Biotechnology Technology
NCT04324996: A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19

Recruiting
1/2
90
RoW
NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells
Chongqing Public Health Medical Center, Chongqing Sidemu Biotech, Zhejiang Qixin Biotech
COVID-19
02/22
08/22
FT536 / Fate Therap
NCT05395052: FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated
1
5
US
FT536, NK Cell Therapy, Cyclophosphamide, Cy, Fludarabine, Flu, IL-2, Interleukin-2, Avelumab, Bavencio, Pembrolizumab, Keytruda, Nivolumab, Opdivo, Atezolizumab, Tecentriq, Trastuzumab, Herceptin, Cetuximab, Erbitux, Amivantamab, Rybrevant
Fate Therapeutics
Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
08/23
08/23
NKX101 / Nkarta Therap
NKX101-101, NCT04623944: NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Active, not recruiting
1
61
US
NKX101 - CAR NK cell therapy, Cyclophosphamide, Fludarabine, Cytarabine (ara-C), Decitabine
Nkarta, Inc.
Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes
10/24
07/39
CLN-619 / Cullinan Therap
NCT06381141: A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

Recruiting
1
30
US
CLN-619
Cullinan Therapeutics Inc.
Multiple Myeloma
09/26
03/27
CLN-619-001, NCT05117476: A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Recruiting
1
410
Europe, US, RoW
CLN-619, Pembrolizumab
Cullinan Therapeutics Inc.
Advanced Solid Tumor
03/26
06/26
DF2001 / Dragonfly Therap
NCT04789655: Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Terminated
1
45
Europe, Canada, US
CC-96191
Celgene
Leukemia, Myeloid
04/25
04/25
DF9001 / Dragonfly Therap
KEYNOTE F92, NCT05597839: Study of DF9001 in Patients With Advanced Solid Tumors

Recruiting
1/2
242
US
DF9001, pembrolizumab, KEYTRUDA®
Dragonfly Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult
08/25
11/27
MK-4464 / Merck (MSD), Dragonfly Therap
MK-4464-001, NCT05514444: Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors

Active, not recruiting
1
260
Europe, Canada, US, RoW
MK-4464, Pembrolizumab, 89Zr-MK-4464
Merck Sharp & Dohme LLC
Advanced/Metastatic Solid Tumors, Neoplasms
03/26
03/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NKG2D-ACE2 CAR-NK cells / Chongqing Sidemu Biotechnology Technology
NCT04324996: A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19

Recruiting
1/2
90
RoW
NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells
Chongqing Public Health Medical Center, Chongqing Sidemu Biotech, Zhejiang Qixin Biotech
COVID-19
02/22
08/22
FT536 / Fate Therap
NCT05395052: FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated
1
5
US
FT536, NK Cell Therapy, Cyclophosphamide, Cy, Fludarabine, Flu, IL-2, Interleukin-2, Avelumab, Bavencio, Pembrolizumab, Keytruda, Nivolumab, Opdivo, Atezolizumab, Tecentriq, Trastuzumab, Herceptin, Cetuximab, Erbitux, Amivantamab, Rybrevant
Fate Therapeutics
Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
08/23
08/23
NKX101 / Nkarta Therap
NKX101-101, NCT04623944: NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Active, not recruiting
1
61
US
NKX101 - CAR NK cell therapy, Cyclophosphamide, Fludarabine, Cytarabine (ara-C), Decitabine
Nkarta, Inc.
Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes
10/24
07/39
CLN-619 / Cullinan Therap
NCT06381141: A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

Recruiting
1
30
US
CLN-619
Cullinan Therapeutics Inc.
Multiple Myeloma
09/26
03/27
CLN-619-001, NCT05117476: A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Recruiting
1
410
Europe, US, RoW
CLN-619, Pembrolizumab
Cullinan Therapeutics Inc.
Advanced Solid Tumor
03/26
06/26
DF2001 / Dragonfly Therap
NCT04789655: Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Terminated
1
45
Europe, Canada, US
CC-96191
Celgene
Leukemia, Myeloid
04/25
04/25
DF9001 / Dragonfly Therap
KEYNOTE F92, NCT05597839: Study of DF9001 in Patients With Advanced Solid Tumors

Recruiting
1/2
242
US
DF9001, pembrolizumab, KEYTRUDA®
Dragonfly Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult
08/25
11/27
MK-4464 / Merck (MSD), Dragonfly Therap
MK-4464-001, NCT05514444: Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors

Active, not recruiting
1
260
Europe, Canada, US, RoW
MK-4464, Pembrolizumab, 89Zr-MK-4464
Merck Sharp & Dohme LLC
Advanced/Metastatic Solid Tumors, Neoplasms
03/26
03/26

Download Options